Key Points
➤ Women with node-positive breast cancer should receive extended therapy
including an aromatase inhibitor (AI) for up to a total of 10 years of
adjuvant endocrine treatment.
➤ Many women with node-negative breast cancer should consider extended
therapy for up to a total of 10 years of adjuvant endocrine treatment based
on considerations of recurrence risk using established prognostic factors.
➤ The benefits in absolute risk of reduction were modest, and, for lower risk
node-negative or limited node positive cancers, an individualized approach
to treatment duration based on considerations of risk reduction and
tolerability was appropriate.
➤ A substantial portion of the benefit for extended adjuvant AI therapy was
derived from prevention of second breast cancers.
